Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGGIC/FIREFLY-2
NCT05566795Phase 3Active, not recruiting
- Sponsor
- Day One Biopharmaceuticals
- Start
- Feb 2023
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 30
01
Overview
A Phase 3 trial of tovorafenib in glioma, sponsored by Day One Biopharmaceuticals. Started Feb 2023; status: active, not recruiting.
02
Drugs
tovorafenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05566795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566795.